ID   SMUF2_HUMAN             Reviewed;         748 AA.
AC   Q9HAU4; Q52LL1; Q9H260;
DT   13-DEC-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   10-MAY-2017, entry version 169.
DE   RecName: Full=E3 ubiquitin-protein ligase SMURF2;
DE            Short=hSMURF2;
DE            EC=2.3.2.26 {ECO:0000250|UniProtKB:Q9HCE7};
DE   AltName: Full=HECT-type E3 ubiquitin transferase SMURF2;
DE   AltName: Full=SMAD ubiquitination regulatory factor 2;
DE   AltName: Full=SMAD-specific E3 ubiquitin-protein ligase 2;
GN   Name=SMURF2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF 251-PRO--VAL-284 AND
RP   297-GLY--LEU-330, AND INTERACTION WITH SMAD7 AND TGFBR1.
RX   PubMed=11163210; DOI=10.1016/S1097-2765(00)00134-9;
RA   Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H.,
RA   Thomsen G.H., Wrana J.L.;
RT   "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the
RT   TGF-beta receptor for degradation.";
RL   Mol. Cell 6:1365-1375(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF 251-PRO--VAL-284 AND
RP   CYS-716.
RX   PubMed=11016919; DOI=10.1074/jbc.C000580200;
RA   Lin X., Liang M., Feng X.-H.;
RT   "Smurf2 Is a ubiquitin E3 ligase mediating proteasome-dependent
RT   degradation of Smad2 in transforming growth factor-beta signaling.";
RL   J. Biol. Chem. 275:36818-36822(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF CYS-716.
RX   PubMed=11158580; DOI=10.1073/pnas.98.3.974;
RA   Zhang Y., Chang C., Gehling D.J., Hemmati-Brivanlou A., Derynck R.;
RT   "Regulation of Smad degradation and activity by Smurf2, an E3
RT   ubiquitin ligase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:974-979(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND INTERACTION WITH SMAD2; SMAD3 AND SNON.
RX   PubMed=11389444; DOI=10.1038/35078562;
RA   Bonni S., Wang H.R., Causing C.G., Kavsak P., Stroschein S.L., Luo K.,
RA   Wrana J.L.;
RT   "TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex
RT   that targets SnoN for degradation.";
RL   Nat. Cell Biol. 3:587-595(2001).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-716.
RX   PubMed=12717440; DOI=10.1038/ncb975;
RA   Di Guglielmo G.M., Le Roy C., Goodfellow A.F., Wrana J.L.;
RT   "Distinct endocytic pathways regulate TGF-beta receptor signalling and
RT   turnover.";
RL   Nat. Cell Biol. 5:410-421(2003).
RN   [7]
RP   ERRATUM.
RA   Di Guglielmo G.M., Le Roy C., Goodfellow A.F., Wrana J.L.;
RL   Nat. Cell Biol. 5:680-680(2003).
RN   [8]
RP   INTERACTION WITH RNF11.
RX   PubMed=14562029; DOI=10.1038/sj.bjc.6601301;
RA   Subramaniam V., Li H., Wong M.J., Kitching R., Attisano L., Wrana J.,
RA   Zubovits J., Burger A.M., Seth A.K.;
RT   "The RING-H2 protein RNF11 is overexpressed in breast cancer and is a
RT   target of Smurf2 E3 ligase.";
RL   Br. J. Cancer 89:1538-1544(2003).
RN   [9]
RP   INTERACTION WITH STAMBP AND RNF11.
RX   PubMed=14755250; DOI=10.1038/sj.onc.1207319;
RA   Li H., Seth A.K.;
RT   "An RNF11: Smurf2 complex mediates ubiquitination of the AMSH
RT   protein.";
RL   Oncogene 23:1801-1808(2004).
RN   [10]
RP   INTERACTION WITH AIMP1.
RX   PubMed=18448069; DOI=10.1016/j.bbrc.2008.04.099;
RA   Lee Y.S., Han J.M., Son S.H., Choi J.W., Jeon E.J., Bae S.-C.,
RA   Park Y.I., Kim S.;
RT   "AIMP1/p43 downregulates TGF-beta signaling via stabilization of
RT   smurf2.";
RL   Biochem. Biophys. Res. Commun. 371:395-400(2008).
RN   [11]
RP   ACTIVATION BY NDFIP1 AND NDFIP2, AND AUTOUBIQUITINATION.
RX   PubMed=19343052; DOI=10.1038/embor.2009.30;
RA   Mund T., Pelham H.R.;
RT   "Control of the activity of WW-HECT domain E3 ubiquitin ligases by
RT   NDFIP proteins.";
RL   EMBO Rep. 10:501-507(2009).
RN   [12]
RP   UBIQUITINATION.
RX   PubMed=21572392; DOI=10.1038/emboj.2011.155;
RA   Cui Y., He S., Xing C., Lu K., Wang J., Xing G., Meng A., Jia S.,
RA   He F., Zhang L.;
RT   "SCF(FBXL15) regulates BMP signalling by directing the degradation of
RT   HECT-type ubiquitin ligase Smurf1.";
RL   EMBO J. 30:2675-2689(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 369-748, INTERACTION WITH
RP   SMAD7, AND MUTAGENESIS OF TRP-535; HIS-547 AND TYR-581.
RX   PubMed=16061177; DOI=10.1016/j.molcel.2005.06.028;
RA   Ogunjimi A.A., Briant D.J., Pece-Barbara N., Le Roy C.,
RA   Di Guglielmo G.M., Kavsak P., Rasmussen R.K., Seet B.T., Sicheri F.,
RA   Wrana J.L.;
RT   "Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to
RT   the HECT domain.";
RL   Mol. Cell 19:297-308(2005).
RN   [14]
RP   STRUCTURE BY NMR OF 297-333 IN COMPLEX WITH SMAD7.
RX   PubMed=16641086; DOI=10.1074/jbc.M601493200;
RA   Chong P.A., Lin H., Wrana J.L., Forman-Kay J.D.;
RT   "An expanded WW domain recognition motif revealed by the interaction
RT   between Smad7 and the E3 ubiquitin ligase Smurf2.";
RL   J. Biol. Chem. 281:17069-17075(2006).
RN   [15]
RP   STRUCTURE BY NMR OF 10-140, AUTOINHIBITION BY C2 DOMAIN, AND
RP   MUTAGENESIS OF PHE-29; PHE-30; THR-56 AND LEU-57.
RX   PubMed=17719543; DOI=10.1016/j.cell.2007.06.050;
RA   Wiesner S., Ogunjimi A.A., Wang H.R., Rotin D., Sicheri F.,
RA   Wrana J.L., Forman-Kay J.D.;
RT   "Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its
RT   C2 domain.";
RL   Cell 130:651-662(2007).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from
CC       an E2 ubiquitin-conjugating enzyme in the form of a thioester and
CC       then directly transfers the ubiquitin to targeted substrates.
CC       Interacts with SMAD1 and SMAD7 in order to trigger their
CC       ubiquitination and proteasome-dependent degradation. In addition,
CC       interaction with SMAD7 activates autocatalytic degradation, which
CC       is prevented by interaction with SCYE1. Forms a stable complex
CC       with the TGF-beta receptor-mediated phosphorylated SMAD2 and
CC       SMAD3. In this way, SMAD2 may recruit substrates, such as SNON,
CC       for ubiquitin-mediated degradation. Enhances the inhibitory
CC       activity of SMAD7 and reduces the transcriptional activity of
CC       SMAD2. Coexpression of SMURF2 with SMAD1 results in considerable
CC       decrease in steady-state level of SMAD1 protein and a smaller
CC       decrease of SMAD2 level. {ECO:0000269|PubMed:11389444,
CC       ECO:0000269|PubMed:12717440}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000250|UniProtKB:Q9HCE7}.
CC   -!- ENZYME REGULATION: Activated by NDFIP1- and NDFIP2-binding.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts (via WW domains) with SMAD1. Interacts (via WW
CC       domains) with SMAD2 (via PY-motif). Interacts (via WW domains)
CC       with SMAD3 (via PY-motif). Interacts with SMAD6. Interacts with
CC       SMAD7 (via PY-motif) and TGFBR1; SMAD7 recruits SMURF2 to the TGF-
CC       beta receptor and regulates its degradation. Does not interact
CC       with SMAD4; SMAD4 lacks a PY-motif. Interacts with AIMP1.
CC       Interacts with STAMBP and RNF11. Interacts with NDFIP1 and NDFIP2
CC       (Probable); this interaction activates the E3 ubiquitin-protein
CC       ligase. {ECO:0000269|PubMed:11163210, ECO:0000269|PubMed:11389444,
CC       ECO:0000269|PubMed:14562029, ECO:0000269|PubMed:14755250,
CC       ECO:0000269|PubMed:16061177, ECO:0000269|PubMed:16641086,
CC       ECO:0000269|PubMed:18448069}.
CC   -!- INTERACTION:
CC       Self; NbExp=6; IntAct=EBI-396727, EBI-396727;
CC       Q9WMX2:- (xeno); NbExp=2; IntAct=EBI-396727, EBI-6863741;
CC       Q9H469:FBXL15; NbExp=3; IntAct=EBI-396727, EBI-6144096;
CC       Q9Y3C5:RNF11; NbExp=5; IntAct=EBI-396727, EBI-396669;
CC       Q15797:SMAD1; NbExp=3; IntAct=EBI-396727, EBI-1567153;
CC       Q15796:SMAD2; NbExp=5; IntAct=EBI-396727, EBI-1040141;
CC       P84022:SMAD3; NbExp=7; IntAct=EBI-396727, EBI-347161;
CC       P0CG47:UBB; NbExp=4; IntAct=EBI-396727, EBI-413034;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12717440}.
CC       Cytoplasm {ECO:0000269|PubMed:12717440}. Cell membrane
CC       {ECO:0000269|PubMed:12717440}. Membrane raft
CC       {ECO:0000269|PubMed:12717440}. Note=Cytoplasmic in the presence of
CC       SMAD7. Colocalizes with CAV1, SMAD7 and TGF-beta receptor in
CC       membrane rafts.
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DOMAIN: The second and third WW domains are responsible for
CC       interaction with the PY-motif of R-SMAD (SMAD1, SMAD2 and SMAD3).
CC   -!- DOMAIN: The C2 domain is involved in autoinhibition of the
CC       catalytic activity by interacting with the HECT domain.
CC   -!- PTM: Auto-ubiquitinated and ubiquitinated in the presence of RNF11
CC       and UBE2D1. Ubiquitinated by the SCF(FBXL15) complex, leading to
CC       its degradation by the proteasome. {ECO:0000269|PubMed:19343052,
CC       ECO:0000269|PubMed:21572392}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF310676; AAG45422.1; -; mRNA.
DR   EMBL; AF301463; AAG25641.1; -; mRNA.
DR   EMBL; AY014180; AAG50421.1; -; mRNA.
DR   EMBL; BC093876; AAH93876.1; -; mRNA.
DR   EMBL; BC111945; AAI11946.1; -; mRNA.
DR   CCDS; CCDS32707.1; -.
DR   RefSeq; NP_073576.1; NM_022739.3.
DR   UniGene; Hs.515011; -.
DR   PDB; 1ZVD; X-ray; 2.10 A; A=369-748.
DR   PDB; 2DJY; NMR; -; A=297-333.
DR   PDB; 2JQZ; NMR; -; A=10-140.
DR   PDB; 2KXQ; NMR; -; A=250-333.
DR   PDB; 2LTZ; NMR; -; A=297-333.
DR   PDBsum; 1ZVD; -.
DR   PDBsum; 2DJY; -.
DR   PDBsum; 2JQZ; -.
DR   PDBsum; 2KXQ; -.
DR   PDBsum; 2LTZ; -.
DR   ProteinModelPortal; Q9HAU4; -.
DR   SMR; Q9HAU4; -.
DR   BioGrid; 122265; 125.
DR   DIP; DIP-33061N; -.
DR   IntAct; Q9HAU4; 68.
DR   MINT; MINT-1180022; -.
DR   STRING; 9606.ENSP00000262435; -.
DR   iPTMnet; Q9HAU4; -.
DR   PhosphoSitePlus; Q9HAU4; -.
DR   BioMuta; SMURF2; -.
DR   DMDM; 17865624; -.
DR   EPD; Q9HAU4; -.
DR   MaxQB; Q9HAU4; -.
DR   PaxDb; Q9HAU4; -.
DR   PeptideAtlas; Q9HAU4; -.
DR   PRIDE; Q9HAU4; -.
DR   Ensembl; ENST00000262435; ENSP00000262435; ENSG00000108854.
DR   GeneID; 64750; -.
DR   KEGG; hsa:64750; -.
DR   UCSC; uc002jep.2; human.
DR   CTD; 64750; -.
DR   DisGeNET; 64750; -.
DR   GeneCards; SMURF2; -.
DR   HGNC; HGNC:16809; SMURF2.
DR   HPA; HPA071508; -.
DR   MIM; 605532; gene.
DR   neXtProt; NX_Q9HAU4; -.
DR   OpenTargets; ENSG00000108854; -.
DR   PharmGKB; PA134985524; -.
DR   eggNOG; KOG0940; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00760000118966; -.
DR   HOGENOM; HOG000208451; -.
DR   HOVERGEN; HBG004134; -.
DR   InParanoid; Q9HAU4; -.
DR   KO; K04678; -.
DR   OMA; QWDRPRQ; -.
DR   OrthoDB; EOG091G011S; -.
DR   PhylomeDB; Q9HAU4; -.
DR   TreeFam; TF323658; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-HSA-4641257; Degradation of AXIN.
DR   Reactome; R-HSA-5632684; Hedgehog 'on' state.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q9HAU4; -.
DR   SIGNOR; Q9HAU4; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; SMURF2; human.
DR   EvolutionaryTrace; Q9HAU4; -.
DR   GeneWiki; SMURF2; -.
DR   GenomeRNAi; 64750; -.
DR   PRO; PR:Q9HAU4; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000108854; -.
DR   CleanEx; HS_SMURF2; -.
DR   ExpressionAtlas; Q9HAU4; baseline and differential.
DR   Genevisible; Q9HAU4; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046332; F:SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IEA:Ensembl.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; TAS:Reactome.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0030509; P:BMP signaling pathway; TAS:Reactome.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:CACAO.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; TAS:Reactome.
DR   GO; GO:1901165; P:positive regulation of trophoblast cell migration; IDA:CACAO.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0000209; P:protein polyubiquitination; TAS:Reactome.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0030579; P:ubiquitin-dependent SMAD protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; TAS:Reactome.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR001202; WW_dom.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00632; HECT; 1.
DR   Pfam; PF00397; WW; 3.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SMART; SM00456; WW; 3.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF51045; SSF51045; 3.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS01159; WW_DOMAIN_1; 1.
DR   PROSITE; PS50020; WW_DOMAIN_2; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Cytoplasm;
KW   Isopeptide bond; Membrane; Nucleus; Reference proteome; Repeat;
KW   Transferase; Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN         1    748       E3 ubiquitin-protein ligase SMURF2.
FT                                /FTId=PRO_0000120329.
FT   DOMAIN        1     98       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      157    190       WW 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      251    284       WW 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      297    330       WW 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      414    748       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   ACT_SITE    716    716       Glycyl thioester intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00104}.
FT   CROSSLNK    375    375       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:Q9HCE7}.
FT   CROSSLNK    377    377       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:Q9HCE7}.
FT   MUTAGEN      29     29       F->A: Increases autoubiquitination; when
FT                                associated with A-30.
FT                                {ECO:0000269|PubMed:17719543}.
FT   MUTAGEN      30     30       F->A: Increases autoubiquitination; when
FT                                associated with A-29.
FT                                {ECO:0000269|PubMed:17719543}.
FT   MUTAGEN      56     56       T->A: Increases autoubiquitination; when
FT                                associated with A-57.
FT                                {ECO:0000269|PubMed:17719543}.
FT   MUTAGEN      57     57       L->A: Increases autoubiquitination; when
FT                                associated with A-56.
FT                                {ECO:0000269|PubMed:17719543}.
FT   MUTAGEN     251    284       Missing: Abolishes interaction with SMAD2
FT                                and SMAD7. {ECO:0000269|PubMed:11016919,
FT                                ECO:0000269|PubMed:11163210}.
FT   MUTAGEN     297    330       Missing: Abolishes interaction with
FT                                SMAD7. {ECO:0000269|PubMed:11163210}.
FT   MUTAGEN     535    535       W->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:16061177}.
FT   MUTAGEN     535    535       W->D: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:16061177}.
FT   MUTAGEN     547    547       H->A: Partial loss of catalytic activity.
FT                                {ECO:0000269|PubMed:16061177}.
FT   MUTAGEN     547    547       H->F,I: Activates autocatalytic activity.
FT                                {ECO:0000269|PubMed:16061177}.
FT   MUTAGEN     581    581       Y->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:16061177}.
FT   MUTAGEN     716    716       C->A: Increases Smad7-bound TGF-beta
FT                                receptors in membrane rafts.
FT                                {ECO:0000269|PubMed:11016919,
FT                                ECO:0000269|PubMed:11158580,
FT                                ECO:0000269|PubMed:12717440}.
FT   MUTAGEN     716    716       C->G: Loss of activity. Loss of ability
FT                                to ubiquitinate SMAD1 and SMAD2 and no
FT                                down-regulation of SMAD1 and SMAD2
FT                                protein levels.
FT                                {ECO:0000269|PubMed:11016919,
FT                                ECO:0000269|PubMed:11158580,
FT                                ECO:0000269|PubMed:12717440}.
FT   CONFLICT      6      6       G -> R (in Ref. 2; AAG45422).
FT                                {ECO:0000305}.
FT   STRAND       12     23       {ECO:0000244|PDB:2JQZ}.
FT   STRAND       35     41       {ECO:0000244|PDB:2JQZ}.
FT   TURN         42     44       {ECO:0000244|PDB:2JQZ}.
FT   STRAND       48     50       {ECO:0000244|PDB:2JQZ}.
FT   STRAND       60     69       {ECO:0000244|PDB:2JQZ}.
FT   STRAND       75     81       {ECO:0000244|PDB:2JQZ}.
FT   HELIX        82     87       {ECO:0000244|PDB:2JQZ}.
FT   STRAND       93     99       {ECO:0000244|PDB:2JQZ}.
FT   HELIX       101    110       {ECO:0000244|PDB:2JQZ}.
FT   STRAND      113    115       {ECO:0000244|PDB:2JQZ}.
FT   STRAND      131    138       {ECO:0000244|PDB:2JQZ}.
FT   STRAND      258    262       {ECO:0000244|PDB:2KXQ}.
FT   TURN        263    265       {ECO:0000244|PDB:2KXQ}.
FT   STRAND      266    271       {ECO:0000244|PDB:2KXQ}.
FT   TURN        272    275       {ECO:0000244|PDB:2KXQ}.
FT   STRAND      276    280       {ECO:0000244|PDB:2KXQ}.
FT   STRAND      282    284       {ECO:0000244|PDB:2KXQ}.
FT   STRAND      286    288       {ECO:0000244|PDB:2KXQ}.
FT   HELIX       293    295       {ECO:0000244|PDB:2KXQ}.
FT   STRAND      301    307       {ECO:0000244|PDB:2DJY}.
FT   STRAND      309    311       {ECO:0000244|PDB:2DJY}.
FT   STRAND      313    317       {ECO:0000244|PDB:2DJY}.
FT   TURN        318    321       {ECO:0000244|PDB:2DJY}.
FT   STRAND      322    326       {ECO:0000244|PDB:2DJY}.
FT   TURN        328    330       {ECO:0000244|PDB:2DJY}.
FT   HELIX       372    386       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      392    397       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       402    411       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       415    419       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      420    426       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       434    449       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       452    454       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      455    460       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      463    469       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       473    475       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       479    495       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       506    512       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       522    525       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       527    538       {ECO:0000244|PDB:1ZVD}.
FT   TURN        542    544       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      549    555       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      558    565       {ECO:0000244|PDB:1ZVD}.
FT   TURN        574    577       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       578    590       {ECO:0000244|PDB:1ZVD}.
FT   TURN        591    594       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       595    608       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       611    614       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       619    627       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      629    631       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       634    639       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      641    646       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       651    662       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       665    676       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      679    681       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       686    688       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      698    702       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      712    714       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       715    717       {ECO:0000244|PDB:1ZVD}.
FT   STRAND      719    722       {ECO:0000244|PDB:1ZVD}.
FT   HELIX       728    739       {ECO:0000244|PDB:1ZVD}.
SQ   SEQUENCE   748 AA;  86196 MW;  3042B443A3755762 CRC64;
     MSNPGGRRNG PVKLRLTVLC AKNLVKKDFF RLPDPFAKVV VDGSGQCHST DTVKNTLDPK
     WNQHYDLYIG KSDSVTISVW NHKKIHKKQG AGFLGCVRLL SNAINRLKDT GYQRLDLCKL
     GPNDNDTVRG QIVVSLQSRD RIGTGGQVVD CSRLFDNDLP DGWEERRTAS GRIQYLNHIT
     RTTQWERPTR PASEYSSPGR PLSCFVDENT PISGTNGATC GQSSDPRLAE RRVRSQRHRN
     YMSRTHLHTP PDLPEGYEQR TTQQGQVYFL HTQTGVSTWH DPRVPRDLSN INCEELGPLP
     PGWEIRNTAT GRVYFVDHNN RTTQFTDPRL SANLHLVLNR QNQLKDQQQQ QVVSLCPDDT
     ECLTVPRYKR DLVQKLKILR QELSQQQPQA GHCRIEVSRE EIFEESYRQV MKMRPKDLWK
     RLMIKFRGEE GLDYGGVARE WLYLLSHEML NPYYGLFQYS RDDIYTLQIN PDSAVNPEHL
     SYFHFVGRIM GMAVFHGHYI DGGFTLPFYK QLLGKSITLD DMELVDPDLH NSLVWILEND
     ITGVLDHTFC VEHNAYGEII QHELKPNGKS IPVNEENKKE YVRLYVNWRF LRGIEAQFLA
     LQKGFNEVIP QHLLKTFDEK ELELIICGLG KIDVNDWKVN TRLKHCTPDS NIVKWFWKAV
     EFFDEERRAR LLQFVTGSSR VPLQGFKALQ GAAGPRLFTI HQIDACTNNL PKAHTCFNRI
     DIPPYESYEK LYEKLLTAIE ETCGFAVE
//
